Efficacy and Safety of Locoregional Radiotherapy With Chemotherapy vs Chemotherapy Alone in De Novo Metastatic Nasopharyngeal Carcinoma: A Multicenter Phase 3 Randomized Clinical Trial

• Published in: JAMA oncology Vol. 6; no. 9; p. 1345
• Main Authors: You, Rui, Liu, You-Ping, Huang, Pei-Yu, Zou, Xiong, Sun, Rui, He, Yu-Xiang, Wu, Yi-Shan, Shen, Guo-Ping, Zhang, Hong-Dan, Duan, Chong-Yang, Tan, Sze Huey, Cao, Jing-Yu, Li, Ji-Bin, Xie, Yu-Long, Zhang, Yi-Nuan, Wang, Zhi-Qiang, Yang, Qi, Lin, Mei, Jiang, Rou, Zhang, Meng-Xia, Hua, Yi-Jun, Tang, Lin-Quan, Zhuang, Ai-Hua, Chen, Qiu-Yan, Guo, Ling, Mo, Hao-Yuan, Chen, Yong, Mai, Hai-Qiang, Ling, Li, Liu, Qing, Chua, Melvin Lee Kiang, Chen, Ming-Yuan
• Format: Journal Article
• Language: English
• Published: United States 01.09.2020
• Subjects: Adult; Antineoplastic Combined Chemotherapy Protocols - administration & dosage; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Cisplatin - administration & dosage; Cisplatin - adverse effects; Female; Fluorouracil - administration & dosage; Fluorouracil - adverse effects; Humans; Male; Middle Aged; Nasopharyngeal Carcinoma - drug therapy; Nasopharyngeal Carcinoma - pathology; Nasopharyngeal Carcinoma - radiotherapy; Neoplasm Metastasis; Progression-Free Survival; Radiotherapy, Intensity-Modulated
• ISSN: 2374-2445
• DOI: 10.1001/jamaoncol.2020.1808

The role of locoregional radiotherapy in patients with de novo metastatic nasopharyngeal carcinoma (mNPC) is unclear. To investigate the efficacy and safety of locoregional radiotherapy in de novo mNPC. Patients with biopsy-proven mNPC, who demonstrated complete or partial response (RECIST v1.1) following 3 cycles of cisplatin and fluorouracil chemotherapy, were enrolled. Eligible patients were randomly assigned (1:1) to receive either chemotherapy plus radiotherapy or chemotherapy alone. Overall, 126 of 173 patients screened were eligible to the study, and randomized to chemotherapy plus radiotherapy (n = 63) or chemotherapy alone (n = 63). Median (IQR) follow-up duration was 26.7 (17.2-33.5) months. The chemotherapy regimens were fluorouracil continuous intravenous infusion at 5 g/m2 over 120 hours and 100 mg/m2 intravenous cisplatin on day 1, administered every 3 weeks for 6 cycles. Patients assigned to the chemotherapy plus radiotherapy group received intensity-modulated radiotherapy (IMRT) after chemotherapy. The primary end point of the study was overall survival (OS). The secondary end point was progression-free survival (PFS) and safety. Overall, 126 patients were enrolled (105 men [83.3%] and 21 women [16.7%]; median [IQR] age, 46 [39-52] years). The 24-month OS was 76.4% (95% CI, 64.4%-88.4%) in the chemotherapy plus radiotherapy group, compared with 54.5% (95% CI, 41.0%-68.0%) in the chemotherapy-alone group. The study met its primary end point of improved OS (stratified hazard ratio [HR], 0.42; 95% CI, 0.23-0.77; P = .004) in favor of chemotherapy plus radiotherapy. Progression-free survival was also improved in the chemotherapy plus radiotherapy group compared with the chemotherapy-alone group (stratified HR, 0.36; 95% CI, 0.23-0.57). No significant differences in acute hematological or gastrointestinal toxic effects were observed between the treatment arms. The frequency of acute grade 3 or higher dermatitis, mucositis, and xerostomia was 8.1%, 33.9%, and 6.5%, respectively, in the chemotherapy plus radiotherapy group. The frequency of late severe grade 3 or higher hearing loss and trismus was 5.2% and 3.4%, respectively, in the chemotherapy plus radiotherapy group. In this randomized clinical trial, radiotherapy added to chemotherapy significantly improved OS in chemotherapy-sensitive patients with mNPC. ClinicalTrials.gov Identifier: NCT02111460.